Sign in Subscribe
health

JNC 8 vs AHA - Why Your Doctor's BP Target Keeps Moving

"Medicine is a science of uncertainty and an art of probability." — William Osler

Your number was fine in 2013. The 2014 expert panel called you healthy. The 2017 American Heart Association update pulled you into the hypertensive column with the very same reading. The 2025 revision tightened the line again and pulled in more people still. You did not change. The target walked toward you twice.

That is not a story about your body. It is a story about a committee, a trial, and a number that keeps moving in one direction. Each move adds people to the medication-candidate column. Some of those moves are defensible. Some are not. Either way, it is worth understanding before you treat the latest threshold as settled fact.

The trial underneath the 2017 drop

The big move was 2017, when the line for stage 1 high blood pressure fell from 140 over 90 down to 130 over 80. The evidence it leaned on was largely a single big trial called SPRINT, published in 2015. SPRINT was a real and careful study, and it found that pushing the top number toward 120 cut heart events in the people it enrolled. The trouble is in who it enrolled and how it measured.

Start with who. SPRINT deliberately left out people with diabetes and anyone with a prior stroke, and the average enrollee was 68 with elevated cardiovascular risk. It did not study young healthy adults, and it did not study the groups it excluded.

Then how it measured. SPRINT used an unattended automated protocol, where the patient sits alone in a quiet room and a machine takes several readings with no nurse, no rushing, and no white-coat jump. That method runs several points lower than a cuff reading in a busy exam room, which is where most people actually get measured. So a SPRINT target of 120 is not the same 120 your clinic cuff shows. Apply the trial's number to the clinic's measurement and the goalpost has quietly moved without anyone deciding to move it.

What each tightening has in common

Step back and the pattern is hard to miss. The 2014 panel, the group known as JNC 8, actually loosened the target for older adults, reading the evidence with a more conservative eye. The 2017 guideline reversed that and tightened. The 2025 revision tightened again and added more people to the column of medication candidates. Each tightening is published as evidence-based, and each one enlarges the pool of people who now qualify for a drug. None of this is a conspiracy. It is what happens when a committee reads a moving evidence base under real pressure not to look soft on a leading cause of death. But the direction is consistent enough that a careful reader should notice it, the same way you would notice any number that only ever moves one way.

Where the real harm hides

Skepticism here is not denial. High blood pressure is genuinely dangerous, and for plenty of people getting it down is what saves them. The harm from an overtightened guideline is usually not the line on the chart. It is the medication added to chase that line past the point where it still helps, with side effects (the lightheadedness, the falls in older adults, the kidney and electrolyte effects SPRINT itself recorded in its intensively treated group) that then get filed under the price of protection. A threshold that turns a healthy 35-year-old into a patient, or that adds a third pill to an 80-year-old to shave a few points off a reading taken in a hurry, can do more harm than those few points were ever going to do.

What it means for your visit

The cuff number does not change because the threshold did. Your physiology, and which of the three levers is feeding your number, is still the actual question. So treat the latest threshold as one input, not the verdict. Know which guideline your doctor is working from. Know which trial it stands on. Ask whether you look like the people that trial enrolled, or like the people it excluded. And remember that a number measured in a rushed exam room is not the number the trial was built on. The threshold is the start of a conversation, not the end of one, and the data you bring (see Bring Your Own Data - What Your Doctor Cannot See) is what turns it back into a decision about you.

The target will probably move again. Your job is to understand the machinery well enough that the next move does not automatically become a new prescription.

Put this to work. A moving threshold is a reason to know your own numbers well, not a reason to distrust the whole enterprise. Bring your own readings, taken properly at home over a couple of weeks, and the conversation stops being about which side of a line a single office reading fell on. The BP log is a free download. Ask what your target is and why it is that number for you specifically. A good clinician will have an answer, and the answer is allowed to be different from the guideline.

References

Sources behind the claims in this piece. Listed at the bottom rather than inline so the prose reads cleanly. Each entry is what actually backs the claim it supports, not adjacent literature.

On how the target moved across guidelines:

On the SPRINT trial behind the 2017 drop, and how it measured blood pressure:

Read next

Comments ()